Showing results (31-40 of 304) with videos related to
Sort By:
Pageof 31
Cancer Letters|May 25, 2005
PTEN and Egr-1 expression in thyroid proliferative lesionsCarla Di Loreto, Gianluca Tell, Marta Pestrin, et al.BMC Cancer|December 21, 2006
Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case reportGianpiero Fasola, Fabio Puglisi, Alessandro Follador, et al.Virchows Archiv : an International Journal of Pathology|June 20, 2013
One-step nucleic acid amplification (OSNA) for intraoperative evaluation of sentinel lymph node status in breast cancer: a comparative study between CK19 protein expression and CK19 mRNA level in primary tumors and lymph node metastasisEnrico Pegolo, Cinzia Puppin, Anna Gerometta, et al.Cancer Treatment Reviews|May 25, 2016
Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly?Caterina Fontanella, Elisa De Carlo, Marika Cinausero, et al.Cancers|January 8, 2023
BRAF and MEK Inhibitors and Their Toxicities: A Meta-AnalysisMattia Garutti, Melissa Bergnach, Jerry Polesel, et al.Cells|June 2, 2021
CDK4/6 Inhibitors in Melanoma: A Comprehensive ReviewMattia Garutti, Giada Targato, Silvia Buriolla, et al.Expert Opinion on Biological Therapy|January 17, 2017
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzleLorenzo Gerratana, Marta Bonotto, Claudia Bozza, et al.Endocrine-Related Cancer|December 3, 2013
Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patientsClaudia Bozza, Fabio Puglisi, Matteo Lambertini, et al.The Oncologist|May 29, 2015
Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?Marta Bonotto, Lorenzo Gerratana, Donatella Iacono, et al.Expert Opinion on Biological Therapy|April 26, 2018
Atezolizumab for the treatment of breast cancerDebora Basile, Giacomo Pelizzari, Maria Grazia Vitale, et al.Pageof 31